The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug–drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

Ageno W.;
2022-01-01

Abstract

The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug–drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.
2022
2022
Farge, D.; Frere, C.; Connors, J. M.; Khorana, A. A.; Kakkar, A.; Ay, C.; Munoz, A.; Brenner, B.; Prata, P. H.; Brilhante, D.; Antic, D.; Casais, P.; Guillermo Esposito, M. C.; Ikezoe, T.; Abutalib, S. A.; Meillon-Garcia, L. A.; Bounameaux, H.; Pabinger, I.; Douketis, J.; Ageno, W.; Ajauro, F.; Alcindor, T.; Angchaisuksiri, P.; Arcelus, J. I.; Barba, R.; Bazarbachii, A.; Bellesoeur, A.; Bensaoula, O.; Benzidia, I.; Bita, D.; Bitsadze, V.; Blickstein, D.; Blostein, M.; Bogalho, I.; Brandao, A.; Calado, R.; Carpentier, A.; Ceresetto, J. M.; Chitsike, R.; Connault, J.; Correia, C. J.; Crichi, B.; De Paula, E. V.; Demir, A. M.; Deville, L.; Doucet, L.; Dounaevskaia, V.; Durant, C.; Ellis, M.; Emmerich, J.; Falanga, A.; Font, C.; Gallardo, E.; Gary, T.; Goncalves, F.; Gris, J. -C.; Hayashi, H.; Hij, A.; Jara-Palomares, L.; Jimenez, D.; Khizroeva, J.; N'Guessan, M.; Langer, F.; Le Hello, C.; Le Maignan, C.; Lecumberri, R.; Lee, L. H.; Liederman, Z.; Lopes dos Santos, L.; Machado, D. H.; Makatsariya, A.; Maneyro, A.; Marjanovic, Z.; Milhaileanu, S.; Monreal, M.; Morais, S.; Moreira, A.; Mukai, M.; Ndour, A.; Correa Oliveira, L.; Otero-Candelara, R.; Tostes Pintao, M. C.; Posch, F.; Prilollet, P.; Rafii, H.; Dias Ribeiro, D.; Riess, H.; Righini, M.; Robert-Ebadi, H.; Rothschild, C.; Roussin, A.; Rueda Camino, J. A.; Ruiz-Artacho, P.; Saharov, G.; Santos, J.; Sebuhyan, M.; Shamseddine, A.; Spectre, G. S.; Taher, A.; Trujillo-Santos, J.; Tzoran, I.; Villiers, S.; Wong, R.; Yamashita, Y.; Yannoutsos, A.; Yasuda, C.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1470204522001607-main.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 338.52 kB
Formato Adobe PDF
338.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2153272
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 171
  • ???jsp.display-item.citation.isi??? 136
social impact